# Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

> **NCT03469349** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 366 (actual)

## Conditions studied

- Peripheral Arterial Diseases

## Interventions

- **DRUG:** Actovegin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03469349
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2019-05-28
- **Final completion:** 2019-08-28
- **Target enrollment:** 366 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03469349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03469349, "Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03469349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*